Metabolic pathways and antimicrobial peptide resistance in bacteria

• Published in: Journal of Antimicrobial Chemotherapy Vol. 79; no. 7; pp. 1473 - 1483
• Main Authors: Elbediwi, Mohammed, Rolff, Jens
• Format: Journal Article
• Language: English
• Published: UK Oxford University Press (OUP) 01.07.2024; Oxford University Press
• Subjects: Anti-Bacterial Agents - pharmacology; Antimicrobial Peptides - genetics; Antimicrobial Peptides - pharmacology; Bacteria - drug effects; Bacteria - genetics; Bacteria - metabolism; Biofilms - drug effects; Drug Resistance, Bacterial; Humans; Metabolic Networks and Pathways - drug effects; Metabolic Networks and Pathways - genetics
• ISSN: 0305-7453; 1460-2091; 1460-2091
• DOI: 10.1093/jac/dkae128

Abstract Antimicrobial resistance is a pressing concern that poses a significant threat to global public health, necessitating the exploration of alternative strategies to combat drug-resistant microbial infections. Recently, antimicrobial peptides (AMPs) have gained substantial attention as possible replacements for conventional antibiotics. Because of their pharmacodynamics and killing mechanisms, AMPs display a lower risk of bacterial resistance evolution compared with most conventional antibiotics. However, bacteria display different mechanisms to resist AMPs, and the role of metabolic pathways in the resistance mechanism is not fully understood. This review examines the intricate relationship between metabolic genes and AMP resistance, focusing on the impact of metabolic pathways on various aspects of resistance. Metabolic pathways related to guanosine pentaphosphate (pppGpp) and guanosine tetraphosphate (ppGpp) [collectively (p)ppGpp], the tricarboxylic acid (TCA) cycle, haem biosynthesis, purine and pyrimidine biosynthesis, and amino acid and lipid metabolism influence in different ways metabolic adjustments, biofilm formation and energy production that could be involved in AMP resistance. By targeting metabolic pathways and their associated genes, it could be possible to enhance the efficacy of existing antimicrobial therapies and overcome the challenges exhibited by phenotypic (recalcitrance) and genetic resistance toward AMPs. Further research in this area is needed to provide valuable insights into specific mechanisms, uncover novel therapeutic targets, and aid in the fight against antimicrobial resistance.